We Give Shareholders a Voice
Levi & Korsinsky, LLP has commenced an investigation into the fairness of the merger of Proteostasis Therapeutics, Inc. (“Proteostasis” or the “Company”) (NASDAQ: PTI) with Yumanity Therapeutics, Inc. (“Yumanity”). Under the terms of the merger, Proteostasis will issue shares of common stock to the owners of Yumanity, with current holders of Proteostasis common stock controlling approximately 32.5% of the combined company.
The Proteostasis merger investigation concerns whether the Board of Proteostasis breached their fiduciary duties to stockholders by agreeing to enter into this transaction and whether the merger undervalues Proteostasis relative to Yumanity, thereby harming Proteostasis shareholders.
To receive more information, please fill out the form.